Inhibitor of dna methylation
CA 2454147 C · Owner: University Of Miami · Inventors: Selker, Eric U.; Jones, Peter A.; Cheng, Jonathan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Zebularine has hypomethylating activity and can be used to inhibit, reverse, and/or reduce DNA methylation in vivo and in vivo. Methods are provided for treating methylation-linked conditions through the application of 2pyrimidinone derivatives, such as Zebularine. Compositions including , pharmaceutical compositions comprising such derivatives are also provided. Also provided are kits for use in inhibiting DNA methylation which kits , include an amount of a 2-pyrimidinone derivative.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 30, 2002 and granted May 21, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 30, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 30, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.